Hanna et al. (35) believed that combination strategies involving IL-10 regulation could improve the efficacy of immunotherapy for chronic lymphocytic leukemia (CLL) and other cancer types. The gene discussed is IL10; the disease is B-cell chronic lymphocytic leukemia.